KROS 8-K 2026-09-28

Keros Therapeutics, Inc. (KROS) 8-K dated 2026-09-28 — accession 0001664710-26-000056. This URL is the filing, not the KROS hub.

Keros Therapeutics, Inc. (KROS) is a biotechnology company listed on US.

Keros Therapeutics, Inc. filed a 8-K on 2026-09-28. Accession 0001664710-26-000056.

Cached items: 7.01, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported KROS revenue for 2025-12-31 was $243.9M. Net income was $87.0M. KROS currently screens at market cap $208.8M.

Not investment advice. The KROS SEC hub lists recent forms. The stock page is the research view.